Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

StemVacs-V iPSC derived dendritic cell immunotherapy - Therapeutic Solutions International

X
Drug Profile

StemVacs-V iPSC derived dendritic cell immunotherapy - Therapeutic Solutions International

Alternative Names: Inducible Pluripotent Stem Cells-derived dendritic cell immunotherapy - Therapeutic Solutions International; Second generation ValloVax - Therapeutic Solutions International; StemVacs-V iPSC; StemVacs-V iPSC-derived dendritic cell immunotherapy

Latest Information Update: 07 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Therapeutic Solutions International
  • Class Cancer vaccines; Dendritic cell vaccines; Immunotherapies
  • Mechanism of Action Macrophage stimulants; Natural killer cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 22 May 2023 Therapeutic solutions International receives approval from the FDA for StemVacs-V for clinical trials in Lung cancer
  • 22 May 2023 Therapeutic Solutions International plans a clinical trial for Lung cancer
  • 01 Nov 2022 Res Nova Bio in-licenses pluripotent stem cells called iPSCs technology from Therapeutic Solutions International
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top